How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/agitation-associated-with-schizophrenia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Agitation associated with Schizophrenia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Agitation associated with Schizophrenia (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Agitation associated with Schizophrenia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Abilify	aripiprazole	Generic (originally Otsuka/BMS)	Third-generation antipsychotic (D2 partial agonist)	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6	2002-11-15
Geodon	ziprasidone	Pfizer Inc.	Atypical antipsychotic (second-generation)	Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A	2001-02-05
Abilify	Abilify	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.		5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6
Zyprexa	olanzapine	Eli Lilly	Atypical Antipsychotic [EPC]	Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Zyprexa	Zyprexa	Washington University School of Medicine		Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Eli Lilly · 1 drug in Agitation associated with Schizophrenia
Generic (originally Otsuka/BMS) · 1 drug in Agitation associated with Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in Agitation associated with Schizophrenia
Pfizer Inc. · 1 drug in Agitation associated with Schizophrenia
Washington University School of Medicine · 1 drug in Agitation associated with Schizophrenia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Agitation associated with Schizophrenia:

Cite this brief

Drug Landscape (2026). Agitation associated with Schizophrenia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/agitation-associated-with-schizophrenia. Accessed 2026-06-10.

Agitation associated with Schizophrenia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing